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Immune responses are orchestrated by a diverse group of functionally specialized, highly differentiated hematopoietic lineages. Surprisingly, such cellular heterogeneity can be established through the coordinated action of relatively few lineage-determining transcription factors. A striking demonstration of this principle is the direct conversion of terminally differentiated B lymphocytes into macrophages, for which redirection into the alternative fate requires only expression of the transcription factors C/EBP-α and C/EBP-β 1 . Similarly, forced expression of key transcription factors in progenitor stages can specify particular mature fates. For example, constitutive activation of the transcription factor Notch1 in hematopoietic stem cells (HSCs) specifies commitment to the T cell lineage 2 . Conversely, deletion of Notch1 redirects HSCs to B cell or natural killer (NK) cell fates 3, 4 .
Although cellular differentiation has been studied extensively in the immune system, understanding of the molecular mechanisms that regulate the development of dendritic cells (DCs) is underdeveloped relative to that of other lineages. DCs bridge two phases of the immune response: the initial recognition of pathogens through pattern-recognition receptors, and specific cell-and antibodymediated clearance 5 . Despite the importance of these cells, their relative paucity and phenotypic similarity to other cells of the mononuclear phagocyte system have confounded analysis. Moreover, DCs comprise several distinct subsets for which precise functions and interrelationships have been difficult to decipher. In this Review, we focus on advances in three areas that have helped to distinguish these cells from related lineages and to determine their function in vivo. First, we discuss the cellular intermediates and branch points of DC development from HSCs. Second, we review evidence that has established classical DCs as a distinct lineage among myeloid cells. Finally, we cover insights into the function of DC subsets gained from understanding the molecular basis of their diversification.
Lineage diversity in the mononuclear phagocyte system Ralph Steinman and colleagues discovered DCs as a unique cell type with 'stellate' or dendritic morphology in preparations of adherent splenocytes 6 . These classical (or conventional) DCs (cDCs) were designated as a distinct lineage on the basis of their remarkable capacity for stimulating naive T cells in mixed-lymphocyte reactions and their biochemical divergence from macrophages [7] [8] [9] . Subsequently, several cell types have been described with phenotypic and functional attributes resembling those of Steinman's cDCs 10 . It has been difficult to determine the relatedness of these cell types on the basis of cell-surface markers and functional responses, as these attributes can overlap among myeloid cells and vary depending on cellular activation status and location in the body 11 . At present, four main cell types are generally categorized as DCs: cDCs, plasmacytoid DCs (pDCs), Langerhans cells and monocyte-derived DCs. We discuss these populations briefly and compare them with the functionally distinct macrophage lineage.
Classical DCs
The cDCs are highly phagocytic, specialized antigen-processing and antigen-presenting cells. A key feature of cDCs is their short half-life (approximately 3-5 days) and continuous replacement from bone marrow precursors, a process dependent on the cytokine Flt3L [12] [13] [14] [15] . Notably, these cells encounter and capture antigens in peripheral tissues and migrate via afferent lymphatic vessels to the T cell zones of secondary lymphoid organs to initiate adaptive immune responses 16 (Fig. 1) . To accomplish these functions, cDCs exist in two distinct functional states 17, 18 . Newly differentiated, immature cDCs have substantial endocytic activity but lower surface expression of major histocompatibility complex (MHC) class I and II proteins. After encountering microbial products or inflammatory stimuli, cDCs undergo considerable cytoplasmic reorganization, transporting peptide-MHC complexes to the cell surface and upregulating costimulatory molecules.
The heterogeneity of cDCs was first demonstrated by the expression of CD8α on a small subset of thymic and splenic DCs; this remains a common way of distinguishing cDC subsets 19, 20 . In addition to CD8α + cDCs, a second and largely complementary subset can be distinguished in lymphoid organs by CD4 expression 21, 22 . These two subsets may have evolved to serve distinct functions 23 . Early studies 1 1 4 6 VOLUME 13 NUMBER 12 DECEMBER 2012 nature immunology r e v i e w determined that CD8α + cDCs are highly efficient at cross-presenting exogenous antigens on MHC class I molecules to CD8 + T cells 24, 25 . In contrast, CD4 + cDCs are generally considered to be poor crosspresenters in vivo but may be more efficient in priming CD4 + T cells through MHC class II-restricted presentation 26, 27 . Studies have identified two cDC subsets in peripheral nonlymphoid organs with analogous functions and developmental requirements [28] [29] [30] [31] [32] [33] . In peripheral tissues, CD8α + cDC equivalents lack their namesake marker but are instead identified by expression of CD103 (integrin α E β 7 ) [31] [32] [33] [34] . Similarly, CD4 is not expressed on the complementary peripheral subset, which can be instead identified by its high expression of CD11b. Here we will consider peripheral CD103 + and lymphoid-resident CD8α + cDCs as one unified subset (although there may be differences due to organ-specific milieus), and CD11b + and CD4 + cDCs as a second, separate lineage 23, 35 .
Human counterparts of CD8α + and CD11b + cDC subsets have also been identified in lymphoid and nonlymphoid organs, which emphasizes the importance of DC lineage diversification across species [35] [36] [37] [38] [39] [40] [41] [42] [43] . Equivalents of CD8α + cDCs in humans, identified by their expression of XCR1, BDCA3 (CD141) and CLEC9A, are also able to cross-present antigens from dead or necrotic cells. In contrast, human DCs that express BDCA1 (CD1c) lack CD8α + cDC-specific functions and transcriptionally resemble mouse CD11b + cDCs 35, 37 .
Plasmacytoid DCs
The pDCs are a distinct lineage on the basis of their morphology, gene expression and ability to secrete large amounts of type 1 interferon after viral encounter [44] [45] [46] [47] . In contrast to the 'dendritic' appearance of cDCs, pDCs have a spherical shape characteristic of antibody-secreting plasma cells. In terms of surface markers, pDCs are distinguished from cDCs by their expression of B220, Siglec-H and Bst2 in mice and of BDCA2 (CD303) in humans [48] [49] [50] [51] . Functionally, pDCs are not phagocytic and maintain a high rate of MHC class II turnover on their cell surface, which renders them inefficient at presenting exogenous antigens to CD4 + T cells 52 . The pDCs are developmentally related to cDCs; both derive from common bone marrow progenitors and require Flt3L for differentiation, although pDCs diverge from cDCs during maturation in the bone marrow 53, 54 . Moreover, after activation, pDCs can acquire some cDC characteristics, such as dendritic morphology, an observation that formed the basis for their original designation as DC precursors 48 .
Macrophages
Unlike DCs, macrophages are nonmigratory, tissue-resident cells that are generally inefficient at antigen presentation. Instead, they have high proteolytic and catabolic activity, which contributes to their ability to scavenge and ingest pathogens, dead cells and cellular debris 55 . At steady state, macrophages are considered to be anti-inflammatory, maintaining organ homeostasis in part by producing regulatory cytokines such as interleukin 10 (IL-10) [56] [57] [58] . Under inflammatory conditions, macrophages can become 'classically activated' and participate in the host response to pathogens 57 .
Although macrophages have been categorized into organ-specific subsets such as bone osteoclasts, liver Kupffer cells, splenic red-pulp Figure 1 The development and migration of mononuclear phagocyte lineages in the steady state. The cDCs, pDCs and monocytes (Mono) derive from bone marrow progenitors. MDPs give rise to CDPs and monocytes. CDPs differentiate into pDCs or committed precursors to cDCs (pre-cDCs). Pre-cDCs, pDCs and monocytes transit through the blood and seed peripheral organs, where pre-cDCs complete their differentiation into CD8 + (or CD103 + ) cDCs or CD4 + (or CD11b + ) cDCs. Monocytes can migrate into tissues and differentiate into macrophages. In the intestine, cDCs and macrophages populate the villi; cDCs are also present in intestinal lymphoid follicles (ILF). In the skin, dermal DCs consist of both CD11b + and CD103 + cDC subsets. Langerhans cells (LC) populate the epidermis and self-renew locally. Macrophages, pDCs and both cDC subsets reside in the lung. A hallmark characteristic of cDCs is their ability to migrate from tissues to draining lymph nodes after encountering antigen, to prime T cell responses. In contrast, macrophages mostly remain at the site of differentiation. r e v i e w macrophages and lung alveolar macrophages, these populations can function similarly after activation and thus may not represent distinct lineages 57 . However, in each organ, tissue macrophage populations can be separated into CD11b hi F4/80 int and CD11b int F4/80 hi subsets 59 . This distinction reflects their derivation from two distinct hematopoietic sources: CD11b hi F4/80 int macrophages originate from HSCderived monocytes, whereas CD11b int F4/80 hi macrophages develop from a yolk-sac macrophage population that emerges before definitive HSC development. These two macrophage populations have some differences in gene expression but are unified in their dependence on macrophage colony-stimulating factor receptor (M-CSFR) and the transcription factor PU.1 for development 59 .
Classically, Langerhans cells (LCs) have been viewed as a DC population in the epidermis [60] [61] [62] . However, they resemble tissue-resident macrophages-particularly, microglia-in several ways. LCs are developmentally dependent on signaling via M-CSFR, express macrophage-specific markers such as F4/80, migrate poorly to lymph nodes relative to the migration of cDCs to lymph nodes, constitutively secrete IL-10 and have an overall gene-expression profile similar to that of macrophages [63] [64] [65] [66] . Furthermore, microglia and LCs arise exclusively from embryonic macrophage and monocyte populations in the steady state and specifically require IL-34 for prenatal development [67] [68] [69] . A reconsidered view might therefore characterize LCs as a macrophage-related lineage rather than a cDC subset, although even this classification is somewhat blurred, as activated LCs have more migratory activity, similar to cDCs but unlike macrophages 62, 64 . Indeed, gene-expression analysis of resident and migratory LC populations has shown that migrated LCs acquire hallmarks of the cDC signature, including expression of genes encoding the Flt3L receptor Flt3, the chemokine receptor CCR7 and the transcription factor Zbtb46 (ref. 66 ).
Monocytes
Monocytes derive from bone marrow progenitors, circulate in the blood and can differentiate into macrophages and DCs 70 . They can be separated into two subsets on the basis of phenotype and function. The Ly6C lo CX3CR1 hi CCR2 lo subset, called 'patrolling monocytes' , migrates along the luminal surface of the vascular endothelium 71 . The close association of these cells with blood vessels allows their rapid recruitment to sites of infection, where they first serve to produce inflammatory mediators and then differentiate into alternatively activated macrophages to initiate tissue repair 70 . The second subset comprises Ly6C hi CX3CR1 lo CCR2 hi cells that have been called 'inflammatory monocytes' . These cells are recruited to sites of infection with slightly delayed kinetics relative to those of patrolling monocytes and differentiate into 'Tip-DCs' (tumor-necrosis factor-and inducible nitric oxide synthase-producing inflammatory DCs). Tip-DCs, which were initially so named because of their dendritic appearance and expression of CD11c, are thought to represent the main inflammatory cell type during infection 72, 73 . In humans, two subsets of monocytes with parallel functions are distinguished by their expression of CD14 (Ly6C hi equivalent) and CD16 (Ly6C lo equivalent) 70, 72 .
The induction of DC differentiation in vitro from human and mouse peripheral monocytes by granulocyte-macrophage colonystimulating factor (GM-CSF) first suggested that monocytes may be an important reservoir for DC development 74, 75 . Like cDCs, GM-CSFderived DCs upregulate their expression of CD11c and MHC class II and efficiently stimulate naive T cells. Although this in vitro system has been widely used, the in vivo equivalent of the GM-CSF-derived DC has been difficult to identify. Tip-DCs, the initial candidate 27, 73, 76 , probably represent activated monocytes rather than cDCs, given their gene-expression pattern and normal development in mice deficient in GM-CSF receptor (GM-CSFR) 11, [77] [78] [79] . Cells induced after microbial stimulation that express the C-type lectin DC-SIGN (CD209a) represent another candidate for the in vivo equivalent of GM-CSF-derived DCs 80 . However, these cells are in fact dependent on signaling via Flt3L and possibly represent activated cDCs that develop independently of monocytes 78 . Finally, studies have suggested that monocytes transferred after depletion of host DC populations can give rise to DCs in the intestine 58, 81, 82 . These donor-derived cells seem to resemble true cDCs by function and phenotype, but their dependence on GM-CSF and gene-expression patterns have not been reported 58, 83 .
DCs develop from progressively restricted bone marrow progenitors DCs in lymphoid organs and peripheral tissues are short-lived, and cells derived from the HSC pool continuously repopulate these DC subsets 14 . Adoptive-transfer studies initially suggested that DCs can arise from either lymphoid-restricted progenitors or myeloidrestricted progenitors 84 . Although the precise contribution of common myeloid progenitors and common lymphoid progenitors to the DC pool is still being debated, a fate-mapping study has determined that ~10% of DCs in lymphoid organs develop from common lymphoid progenitors, which suggests that ~90% derive from common myeloid progenitors 85 . Macrophage-DC progenitors (MDPs), the first precursor population downstream of the common myeloid progenitor that retains DC potential 86, 87 , give rise to pDCs, cDCs, monocytes and macrophages but not neutrophils or other myeloid lineages. However, whether MDPs truly represent a clonal source of both M-CSF-dependent macrophages and Flt3L-dependent DCs is still under investigation (K. Shortman, personal communication). Subsequently, a common DC progenitor (CDP) 53, 54 has been identified that retains only cDC and pDC potential 53, 54 . Like MDPs, CDPs have high expression of M-CSFR and Flt3 but lower expression of the stem-cell factor receptor c-Kit 87 . At a clonal level, CDPs are able to generate all DC subsets 53 and seem to represent the immediate precursor of pre-cDCs, which are cDC restricted but immature 88, 89 . Pre-cDCs seed lymphoid and nonlymphoid tissues via the blood and then complete their differentiation into CD8α + or CD11b + cDCs (Fig. 1) . In contrast, pDCs mature in the bone marrow and emigrate through the blood to secondary lymphoid organs. Unlike fully differentiated CCR9 + pDCs, immature CCR9 − pDCs can differentiate into cDC subsets in vitro and in vivo 90 , which suggests that pDC development can be redirected until the terminal stage of maturation 91 .
Flt3L and M-CSF are the two main regulators of the development of DCs and macrophages, respectively 92 . Flt3 expression is maintained throughout DC development and on terminally differentiated DCs but not on macrophages 66, 92 . Loss of Flt3L or of Flt3 or its downstream signaling molecule STAT3 results in considerably fewer DCs in vivo 12, 13, 15, 93 . Conversely, forced expression of Flt3 on Flt3 − progenitors restores their ability to give rise to DCs in vivo 94 . Flt3 signaling serves to promote CDP proliferation as well as the homeostatic expansion of DC populations 15 . In contrast, M-CSFR is maintained on mature macrophages and is progressively downregulated on DCs 66, 92 . Loss of M-CSFR specifically impairs the development of monocytes and macrophages, but loss of Flt3 does not 95 . However, the dichotomy between Flt3 and M-CSFR is an oversimplification, as other cytokines seem to have a role in development. For example, the combined loss of GM-CSF and Flt3L generates a much greater decrease in DC development than does loss of Flt3L alone 96 . Similarly, loss of lymphotoxin signaling leads to a lower abundance of DCs selectively in the spleen and intestine but not in other peripheral tissues 97, 98 . Surface-marker limitations in distinguishing myeloid lineages For some time, CD11c was the main surrogate marker for DC identification; its locus has been modified to express fluorescent reporters, Cre recombinase or diphtheria toxin receptor (DTR) to allow the tracking, deletion or inducible depletion of DCs in vivo [99] [100] [101] . However, the interpretation of studies based on such models has been confounded by CD11c expression in other lineages 102, 103 . For example, administration of diphtheria toxin A in CD11c-DTR mice results in the depletion of cDCs and pDCs, along with tissueresident, marginal-zone and metallophilic macrophages, as well as NK cells, NKT cells and some CD11c + B cells and T cells 65, 104, 105 . So far, no single surface marker has been identified that can be used to uniquely distinguish DCs from cells of other myeloid or lymphoid lineages. The identification of subsets in the cDC lineage through the use of surface markers can also be problematic. For example, although CD103 is commonly used to identify peripheral CD8α + cDCs, it is also expressed on CD11b + cDCs in the intestine and lung 33, 81 . Furthermore, CD103 is dynamically regulated by many cytokines, including GM-CSF, IL-3 and TGF-β [106] [107] [108] . This has generated some debate about whether GM-CSF regulates the development of peripheral CD103 + cDCs and intestinal CD11b + cDCs or merely controls CD103 expression 79, 81, 106, 109 . One study has reported that CD103 + CD11b − cDCs develop in all organs but have lower expression of CD103 in the absence of GM-CSFR 106 . In contrast, another study has reported a nearly complete absence of CD103 + cDCs in the peripheral tissues of GM-CSFR-deficient mice 79 . Through the use of mixed-bone marrow chimeras, however, that study concluded that GM-CSFR-deficient CD103 + cDCs can indeed develop but have diminished survival relative to that of wild-type cDCs. Consistent with that, the development of DC progenitors was unaffected in that setting 79 .
Additional loci have been targeted to express fluorescent proteins to define myeloid lineages in vivo, including those encoding LysM, M-CSFR, CX3CR1 and CD11b, but they are also dynamically regulated and expressed outside the DC lineage 65 . Such difficulties have prompted suggestions that the identification of true cDC populations may require simultaneous analysis of surface phenotype, cellular derivation, function and anatomical location 11 , or even that the effort may be inherently futile 65 .
Refining lineage relationships through transcriptional programs
The expression database of the Immunological Genome Project includes more than 50 macrophage and DC subsets, which makes possible an unbiased assessment of genetic relationships among cell types 66, [110] [111] [112] . Through the use of principal-component analysis (PCA), correlated variables from these high-dimensional data sets are presented in fewer uncorrelated principal components that represent the variance among samples (Supplementary Note). In PCA of several macrophage and DC samples, more than two thirds of the variation in gene expression is captured in three principal components, which segregate cell types by anatomical location (Fig. 2a) and by lineage independently of location (Fig. 2b) . When genes are ordered by their relative 'weight' , or 'loading' , in principal component 3, the most positive 'loadings' correspond to genes such as Flt3 and Xcr1, which encode molecules known to be involved in the development and function of DCs but not macrophages; the most negative 'loadings' correspond to C1q and Ctsd, which encode molecules that function specifically in macrophages (Fig. 2b) . In extensive examinations of DC and macrophage populations, several groups have observed similar segregation by organ and lineage by PCA 66, 111, 112 . Notably, PCA that incorporates LCs has consistently positioned these cells closer to macrophages 66 or, specifically, to microglia (X.W., unpublished data) than to cDCs along the lineage-associated principal component.
Such analyses suggest that approaches beyond surface markers may be possible for the separation of lineage from the effects of maturity and anatomical location. The transcription factor Zbtb46 has been identified as a marker specifically expressed by cDCs in lymphoid and nonlymphoid tissues but not by other myeloid or lymphoid cell types 77, 78 . Through the use of DTR-based ablation or a green fluorescent protein (GFP) reporter, such studies have demonstrated that a transcription factor-based approach can be useful in distinguishing DCs from macrophages. In peripheral organs such as the lung, Zbtb46 is uniformly expressed in CD11c + CD103 + CD11b − and CD11c + CD103 + CD11b + cDC populations, which confirms their cDC classification, but not in CD11c + SSC hi CD103 − CD11b lo−neg macrophages. In addition, Zbtb46 is expressed in nearly half of CD11c + CD103 − CD11b + cells, which demonstrates previously unappreciated heterogeneity in this population. In contrast, 77 or by intravital two-photon microscopy (Z. Shulman and M.C. Nussenzweig, personal communication). Visualization of CD169 + subcapsular sinus macrophages has shown that a subset of these cells express Zbtb46. It is still unclear whether such heterogeneity is related to the transfer of CD169 between subcapsular sinus macrophages and innate lymphocytes 113 , which further motivates the development of additional transcription factor-based lineage-tracking approaches. An unanticipated utility of the Zbtb46-GFP reporter has emerged from its heterogeneous expression by previously defined DC progenitor populations 77 . In the CDP and pre-cDC gates, Zbtb46 expression identifies a subset of cells with completely extinguished pDC potential, whereas pre-cDCs identified by previous demarcations retain appreciable pDC output 77, 89 . Specifically, pre-cDCs are subcategorized into four populations on the basis of their expression of Zbtb46-GFP and the lectin Siglec-H. Zbtb46-GFP + cells generate cDCs but not pDCs regardless of Siglec-H expression. In contrast, Siglec-H + Zbtb46-GFP − cells are not committed to the pDC lineage and can induce Zbtb46 expression and generate cDCs. Hence, expression of Siglec-H on pre-cDCs may identify a population that overlaps the CCR9 − pDC-like precursors 90 . Combining Zbtb46-GFP with additional markers may further resolve the issue of the potentials of DC progenitors and, perhaps, identify the basis for the divergence of CD8α + cDCs and CD11b + cDCs.
More generally, transcription factor-based reporters may help to distinguish other mature myeloid lineages and clarify lineage potentials in the progenitor stages as presently defined. Whereas Zbtb46 expression is positively correlated with the lineage-segregating component score by PCA, expression of Mafb (which encodes the transcription factor MafB) shows an inverse pattern (Fig. 2c) . Indeed, both genes are key elements of the core transcriptional signature of cDCs and macrophages, respectively 66, 112 . Thus, MafB reporter mice may be used to more accurately identify stages of macrophage commitment 114 (Fig. 3) . Similarly, pDC development may be clarified by reporters for the lineage-specific transcription factors E2-2 (refs. 115,116), Spi-B 117 and Duxbl, whereas a reporter for the transcription factor IRF8 could help distinguish DC-committed progenitors from MDPs 118 (Fig. 3) .
Transcription-factor networks regulate DC subset heterogeneity Reviews of DC development have distinguished between transcription factors that act generally in the development of cells of the immune system and those that act specifically in DC lineages 91, 119 . Factors of the first kind include Ikaros, PU.1 and Gfi1, which regulate genes that encode molecules required for early hematopoiesis, such as Flt3, Il7r and Stat3 (refs. 120-125) . Whether these factors also exert DC-restricted actions has not been examined by lineage-specific conditional deletion. Here we will focus on factors of the second kind, which regulate development of DC subsets and allow their functional analysis.
CD8a + cDC transcription factors DC development is greatly affected by IRF8, one of nine members of the IRF family of transcription factors. IRF8 deficiency causes complete loss of pDCs and CD8α + cDCs 126 . In the setting of competitive bone marrow reconstitution, IRF8 is also important for the development of CD11b + cDCs 118 . The perturbed development of all cDC subsets in the absence of IRF8 indicates that this factor acts very early in DC-committed progenitors (Fig. 4a) ; accordingly, in the absence of IRF8, there are considerably fewer CDPs but an associated greater abundance of neutrophil precursors 118 . Among potential gene targets of IRF8 that may be key in fate restriction, several are known to encode transcription factors that regulate DC development 118 (Fig. 4a) . Id2 is induced in vitro by GM-CSF and is required in vivo for development of CD8α + cDCs but not of other subsets 127 . Bcl-6 is induced at the pre-cDC stage and is required for development of CD11b + and CD8α + cDCs but not pDCs 128 . KLF4 and Bach2 have high expression in DC progenitors and mature DCs 110 ; loss of KLF4 results in a moderately lower abundance of CD11b + cDCs 129 , but no role for Bach2 in DCs has yet been reported.
Unlike IRF8, the AP-1 transcription factor BATF3 is expressed in both CD11b + cDCs and CD8α + cDCs but is required for normal development of only the latter subset 33, 130 . BATF3 forms a heterodimer with paralogs of the transcription factor Jun but lacks the carboxy-terminal transcriptional activation domain found in Fos, the classical AP-1 partner of Jun 131 . BATF3 does not influence the development of progenitor cells such as CDPs or pre-cDCs but instead acts in the final stages of the development of CD8α + cDCs 33 . Interestingly, CD8α + cDCs can be found in skin-draining lymph nodes of C57BL/6 138 . Similarly, a requirement for IRF4 has been reported for the development of CD11b + cDCs 138 . This factor interacts with PU.1 and can either activate or repress gene expression 139 . It is not yet known how IRF4 and RelB act to regulate CD11b + cDCs or what signal is responsible for their induction in developing progenitor cells. Moreover, additional analysis of these factors with a more complete array of surface markers and reporter strains is needed to explain some previous observations. For example, loss of IRF4 results in more CD11c + CD4 − CD8α − cells, but the identity of these cells has not been evaluated 138 .
The recognition that canonical signaling via the receptor Notch2 regulates the development of CD11b + cDCs represents an important advance 98, 101 . Mice deficient in RBP-J, a mediator of the Notch signaling pathway, have a 50% lower abundance specifically of splenic CD11b + cDCs 101 . It has since been recognized that splenic CD11b + cDCs comprise two subsets distinguished by expression of the chemokine receptor CX3CR1 and the adhesion molecule ESAM; Notch2 is required specifically for development of CX3CR1 lo ESAM hi cells, but other receptors of the Notch family are not 98 . Although both subsets of splenic CD11b + cDCs are dependent on Flt3 signaling, the Notch2-dependent cells selectively require the lymphotoxin-β receptor for development. Because that receptor is required for the homeostasis of splenic DC subsets 97 , Notch2 might act by promoting the interaction of DC Batf3 −/− mice at steady state and in additional organs after the administration of 132) . This compensatory development relies on the related factors BATF and BATF2 to form DNA-binding complexes of AP-1 and IRF proteins 132 . Analysis of Id2-GFP reporter mice has demonstrated the sequential requirement for IRF8, Id2 and BATF3 in the development of CD8α + cDCs 108 (Fig. 4a) . That study confirmed that BATF3 acts only in the final maturation stage of CD8α + cDCs, during which CD103 is induced, whereas IRF8 is required for the development of all Id2-expressing cDC progenitors. NFIL3 has been identified as another transcription factor required for the development of CD8α + cDCs 133 . Batf3 expression is lower in Nfil3 −/− DC progenitors than in their wild-type counterparts, and Batf3 overexpression bypasses the requirement for NFIL3 in CD8α + cDCs, which suggests that NFIL3 may act upstream of BATF3; however, additional analysis is needed to place this factor in the context of IRF8 and Id2.
Orthologous factors may act in the specification and commitment of human and mouse DC subsets. For example, human BDCA3 + cDCs and BDCA1 + cDCs, the equivalents of mouse CD8α + cDCs and CD11b + cDCs, respectively 134 , show IRF8 dependence 135 . A patient who presented with severe opportunistic infections was found to have a mutation of IRF8 that produces the K108E mutant of IRF8, which results in the loss of its DNA-binding and transactivation activity 135 . That deficiency in IRF8 results in the loss of monocytes, pDCs and both cDC subsets, which suggests that IRF8 also acts at an early stage of DC development in humans. Human BDCA3 + cDCs also show a dependence on BATF3; knockdown of BATF3 in human cord blood progenitor cells specifically leads to the diminished development of CLEC9A + BDCA3 + cDCs in vitro 134 .
CD11b + cDC transcription factors
The first transcription factor observed to regulate the development of a specific DC subset was the NF-κB family member RelB 136, 137 . Mice deficient in RelB have considerably fewer CD11b + cDCs because r e v i e w precursors with marginal-zone cells that produce lymphotoxin-α 1 β 2 . Deficiency in Notch2 (or, presumably, the lymphotoxin-β receptor) does not affect migratory DCs in tissues other than the intestine, which lacks all CD11b + CD103 + cDCs. Those results confirm the proposal that intestinal CD11b + CD103 + cDCs are not related to the BATF3-dependent CD103 + cDCs present in other peripheral tissues but instead represent an intestinal equivalent of CD11b + lymphoid cDCs. Further, ESAM lo DCs are thought to derive from MDPs independently of pre-cDCs 98 , although it is possible that ESAM hi and ESAM lo CD11b + cDCs arise from a common progenitor cell in which the terminal fate is determined at the anatomical site of maturation. Finally, Notch2 may also regulate the development of CD8α + cDCs, but the extent of this effect-and how much it may coincide with the role of this factor in CD11b + cDCs-requires additional analysis 98 .
The pDC transcription factors
The transcription factor E2-2 is specifically required for pDC development in both mice and humans 115 . E2-2 is a member of the class I basic helix-loop-helix family, along with three other factors: E12, E47 and HEB 140 . These E proteins form dimers with each other that bind conserved E-box DNA motifs, an action that can be interrupted when E proteins form dimers instead with proteins of the inhibitor-ofdifferentiation helix-loop-helix family, such as Id2. Indeed, in pre-cDCs, inhibition of E2-2 by Id2 may divert cells away from differentiation into pDCs and redirect them along the cDC pathway. Overexpression of Id2 inhibits in vitro pDC development 141 , whereas conditional deletion of the gene encoding E2-2 in mature pDCs results in the re-expression of many genes not associated with pDC identity, including Id2 itself 116 . Furthermore, Id2 −/− mice have a greater abundance of pDCs than do wild-type mice 127 , although more detailed analysis with pDC-specific markers may be warranted. Direct transcriptional targets of E2-2 in pDCs, identified by chromatin immunoprecipitation followed by microarray analysis, include the transcription factor-encoding genes Spib, Irf8 and Bcl11a, as well as several genes that encode molecules associated with pDC function, such as Tlr7, Tlr9 and Bdca2 (refs. 115,116) . In fact, both Spi-B and Bcl-11a have now been hypothesized to have roles in pDC development 116, 117 .
Functions of DC subsets determined by genetic models Various genetic models, including transcription factor-deficient mice, have helped to advance the understanding of DC function (Fig. 4b) . To address the imperfect separation of cDC and macrophage functions through the use of CD11c-based systems 103, 142 , studies have compared CD11c-DTR and Zbtb46-DTR mice in the context of infection with Toxoplasma gondii and tumor growth 78 . The depletion of cells mediated by diphtheria toxin A leads to much greater impairment of immune responses in CD11c-DTR mice than in Zbtb46-DTR mice in either model, with a greater pathogen burden, less antigenspecific T cell priming and more tumor growth. Such results indicate that populations deleted from CD11c-DTR mice but not from Zbtb46-DTR mice actively contribute to immunological defenses. Thus, assessment of cDC-specific functions in vivo may benefit from reevaluation with the more stringent Zbtb46-DTR system. Similar insights into the role of the CD8α + cDC have been gained through the study of mice deficient in BATF3 or IRF8. Although studies of IRF8-deficient mice have indicated that CD8α + cDCs are a source of IL-12 during infection by T. gondii 143 , these mice have additional changes in other myeloid lineages, B cell development and expression of interferon-γ-inducible genes, all of which may contribute to altered immune responses 144, 145 . Because Batf3 −/− mice show a more selective defect restricted to CD8α + cDCs, studies of these mice have helped confirm that CD8α + cDCs are the critical source of IL-12 that limits early infection with T. gondii 130, 146 . The capacity for robust IL-12 production, which may be facilitated by the expression of innate sensors such as Toll-like receptor 11, demonstrates that cross-presentation ability is not the only consequence of CD8α + cDC specialization 146 . Studies of Batf3 −/− mice have also helped to clarify the role of CD8α + cDCs as an obligate entry point in promoting the early spread of Listeria monocytogenes from the marginal zone to the splenic lymphoid areas in a model of blood-borne infection 147, 148 . Furthermore, analysis of Batf3 −/− mice and Ifnar1 −/− mice together has shown that CD8α + cDCs need type I interferon signaling to promote their antitumor activity 149, 150 . That finding agrees with studies indicating that cross-presentation by CD8α + cDCs may require maturation induced by GM-CSF or activation of Toll-like receptors 108, 151 .
Analysis of Batf3 −/− mice has also led to the exclusion of some proposed actions of CD8α + cDCs. For example, CD8α + cDCs are apparently not essential for the development of regulatory T cells 130, 152 . Likewise, CD103 + cDCs are dispensable for the induction of experimental autoimmune encephalitis 106 , which contradicts past suggestions 109 , and they are not required for colitis induced by dextran sodium sulfate or for contact hypersensitivity 33 , which clarifies published conflicting results 28, 153 . And although CD8α + cDCs are required for the priming of CD8 + T cells in response to West Nile virus 130, 154 , herpes simplex virus 155 and mouse cytomegalovirus 156 , they are not required for the accumulation of immunodominant T cells specific to mouse cytomegalovirus during latency 156 . Finally, priming of CD8 + T cells in response to some viruses such as lymphocytic choriomeningitis virus may occur normally in the absence of CD8α + cDCs (A. Pinto and M. Diamond, personal communication), although reports of such negative results are still awaiting publication.
In contrast to the functions of CD8α + cDCs, the unique functions of CD11b + cDCs remain to be determined, in part because of the lack of genetic models with selective deletion of this subset. Progress along these lines has been made by conditional deletion of Notch2 through the use of CD11c-Cre, which causes a defect in the priming of CD4 + T cells and production of IL-17 by intestinal CD4 + T cells 98 . Those findings are consistent with published reports showing that CD11b + cDCs can support priming of the T H 17 subset of helper T cells in vitro 56 and that CD11b + cDCs produce IL-23 in response to signaling via Toll-like receptor 5 (ref. 157) . Thus, cDC subsets may specialize in selectively priming CD4 + T cells along different developmental pathways (Fig. 4b) . That interpretation is consistent with a scheme in which CD11b + cDCs stimulate innate lymphoid cells to produce IL-22 during infection, an important pathway for resistance to attaching and effacing bacteria such as Citrobacter rodentium 158, 159 .
Finally, genetic models have contributed to the definitive attribution of pDC function. Studies of mice in which DTR is expressed under the control of the promoter of the pDC-specific gene encoding BDCA2 have shown that pDCs are required for the early production of type I interferon after viral challenge 160 . Deletion of pDCs does not substantially alter viral burden or T cell priming after viral challenge, which eliminates the possibility of antigen presentation as a major function of pDCs. Instead, pDCs induce the early activation of NK cells and promote the survival of CD8 + T cells after their population expansion. Those findings have been confirmed through the use of a model in which the gene encoding E2-2 is specifically deleted by CD11c-Cre, with which it has been shown that pDCs are particularly critical for controlling chronic viral infection. In this setting, the observed effect on T cell survival is mediated directly by pDC-dependent production of interferon and is not a result of antigen presentation 161 . Concluding remarks Advances in cell-isolation techniques have made possible the purification of committed populations of DC progenitors, the creation of microarray databases and the identification of transcription factors that have led to animal models in which DC development can be manipulated in vivo. The resulting picture indicates that DCs are in fact a lineage distinct from macrophages, with unique and nonredundant functions. Future work with genetic depletion models and with a range of pathogens will form the basis of a more comprehensive understanding of the functions of specific DC subsets. At the molecular level, research has begun to clarify the transcriptional mechanisms that control DC development. This has included identification of the roles of E2-2, BATF3, NFIL3 and Notch2 in commitment to DC subsets and in-depth analysis of IRF8 and Id2, which has provided a hierarchical structure for the actions of these factors in developing progenitor cells. However, many key questions still remain. The critical divergence between macrophages and DCs remains unexplained. Similarly, the basis for the bifurcation of the CD11b + and CD8α + cDC lineages remains to be defined. As with T cells or B cells, full understanding of the stage-specific actions of transcription factors and their gene targets will benefit from unbiased genome-wide approaches such as microarray analysis, chromatin immunoprecipitation followed by deep sequencing, and newer modalities. Ultimately, such work on DCs, particularly in humans, could have a direct bearing on approaches to improve vaccine design for infections and malignancies.
